Subscribe

Meet the ARK
Board Of Directors

The ARK Board of Directors oversees ARK’s full commitment to creating long-term value for our clients. ARK aims to be a driving force and thought-leader when it comes to investing in disruptive innovation. Our leadership embraces this vision and supports ARK on this journey.

Meet the ARK<br>Board Of Directors
Catherine D. Wood Founder, Chief Investment Officer, Chief Executive Officer of ARK Invest

Catherine D. Wood is the Founder, CEO, and CIO of ARK. Cathie registered ARK Investment Management LLC (“ARK”) as an investment adviser with the U.S. Securities and Exchange Commission in January 2014. As Chief Investment Officer (“CIO”) and Portfolio Manager, Cathie led the development of ARK’s philosophy and investment approach and has ultimate responsibility for investment decisions. Prior to ARK, Cathie spent twelve years at AllianceBernstein as CIO of Global Thematic Strategies where she managed over $5 billion. Cathie joined Alliance Capital from Tupelo Capital Management, a hedge fund she co-founded, which in 2000, managed approximately $800 million in global thematic strategies. Prior to her tenure at Tupelo Capital, she worked for 18 years with Jennison Associates LLC as Chief Economist, Equity Research Analyst, Portfolio Manager and Director. She started her career in Los Angeles, California at The Capital Group as an Assistant Economist. Cathie received her Bachelor of Science, summa cum laude, in Finance and Economics from the University of Southern California in 1981.

Gene L. Needles, Jr. Chairman and CEO of Resolute Investment Managers

Gene L. Needles, Jr. serves as chairman and CEO of Resolute Investment Managers, the parent company of American Beacon Advisors, Inc. He also serves as chairman and CEO of American Beacon Advisors and president of American Beacon Funds, and holds additional senior leadership positions with other organizations affiliated with the company. Prior to joining American Beacon Advisors in 2009, he served as president of Touchstone Investments, part of the Western & Southern Financial Group. From 1993 through 2007, Mr. Needles was with AIM Investments and subsequently Invesco (through the merger of AIM and Invesco), progressing from regional vice president to president and CEO of Invesco Distributors in 2004. In this role, he was responsible for distributing products that included mutual funds, exchange-traded funds, separate accounts, variable annuities, sub-advised portfolios, collective trusts, offshore funds, retirement plans and college savings plans. In addition, he worked as a vice president at Putnam Investments and MetLife State Street before moving to AIM. Mr. Needles received his B.A. in English from Iowa State University in 1978.

Gary H. Neems Former Chief Operating Officer of CIFC Corporation

Gary H. Neems served as the Chief Operating Officer of CIFC Corporation until December 2012. Mr. Neems was a Co-Founder, Co-Chief Executive Officer, Managing Director, and Member of Investment Committee of Callidus Capital Management, LLC. Prior to co-founding Callidus, Mr. Neems was a Co-Managing Partner of Advanta Partners LP (1995-2000). From 1993-1995, after leaving Equitable, he was a Managing Director and Partner of Clipper Capital Partners, an investment affiliate of CS First Boston, focused on making and managing private equity investments. Prior to this, he served as a Managing Director and Investment Group Head within the Corporate Finance Department of Equitable Capital Management Corporation from 1989 to 1993. He managed a group with approximately $2 billion in assets in a diversified group of industries and was a member of the department’s Investment Committee. He started his career in 1977 at Citibank. He has or currently sits on the board of directors of a number of companies. Mr. Neems earned a B.A. in Chemistry from the University of Rochester and an M.B.A. in Finance from the University of Rochester Simon Graduate School of Business.

Tomoko Ueda Global Head of Strategic Planning and Management Information at Nikko Asset Management

Tomoko Ueda joined Nikko Asset Management (Nikko AM) in September 2013 and is the Global Head of Strategic Planning and Management Information, responsible for the Nikko AM Group’s strategic activities, including joint ventures, partnerships and mergers & acquisitions. Ms. Ueda is based in Tokyo, Japan, the Group’s Headquarters. Ms. Ueda led Nikko AM’s investment in ARK Invest in 2017 and has been actively involved in the development of ARK/Nikko AM relationship. Ms. Ueda also oversees the Group’s joint ventures in China (Rongtong Fund Management) and in Malaysia (Affin Hwang Asset Management). Prior to joining Nikko AM, Ms. Ueda was Managing Director at Merrill Lynch Japan Securities from 2010 and at Morgan Stanley from 1996, where she served as Head of Equity Capital Markets, responsible for the origination and execution of equity and equity-linked financing. Ms. Ueda started her investment banking career at Morgan Stanley in London, and has over 16 years’ experience advising clients in Europe and Japan on capital raising and mergers & acquisitions transactions. Prior to investment banking, Ms. Ueda worked at the United Nations in New York, having served in election monitoring missions in Eritrea and South Africa, and at Mercer Management Consulting in Boston. Ms. Ueda has an MBA from Stanford University Graduate School of Business, and MA and BA in history from University of Pennsylvania.

John Duddy Former VP of Corporate Marketing at Thermo Fisher Scientific

John served as Vice President, Corporate Marketing at Thermo Fisher Scientific, Inc. where he was responsible for global marketing, strategy and digital transformation until December, 2019. From 2012 through 2015, he led global marketing and strategy for the company’s innovative chromatography and mass spectrometry business. Prior to Thermo Fisher, Mr. Duddy led global marketing at Sciex, a division of Danaher, Inc. from 2010 to 2012. From 2003 to 2009, he was Vice President, Global Marketing Group and regional marketing at Applied Biosystems, Inc., a leader in DNA sequencing, before the acquisition by Invitrogen (Life Technologies). Through 2010, he worked on the global integration and development of the Americas marketing organization as part of the new company. Earlier in his career, Mr. Duddy progressed through leadership roles at American Hospital Supply, Baxter, Inc. as well as Eli Lilly, Inc. where he led corporate accounts and sales for their diagnostic business until the acquisition by Beckman Coulter (now part of Danaher). As part of Beckman Coulter, Mr. Duddy was national sales manager overseeing sales, marketing and technical support for their clinical diagnostic point-of-care business. Mr. Duddy received a Bachelor of Science in Business Administration from the University of Southern California in 1981.